drugset / Trial / NCT00740116

Tranexamic Acid in Surgery of Advanced Ovarian Cancer

NCT00740116

Phase 4 Completed 100 enrolled Preben Kjolhede, MD, professor
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine if a standardized single dose tranexamic acid given intravenously immediately preoperatively reduces the perioperative bleeding volume and reduces the need of blood transfusion in women undergoing surgery for advanced ovarian cancer.

Timeline

Start
2008-03
Primary completion
2012-06
Completion
2012-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 15 mg/kg Intravenous

Indications